AzTrials
AzTrials

Cesarean Section, Affecting Fetus or NewbornPhase 1NCT02715154

Dexmedetomidine for Cesarean Section

A Phase 1 study testing Dexmedetomidine in people with Cesarean Section, Affecting Fetus or Newborn, run by The First Affiliated Hospital with Nanjing Medical University at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Current cesarean section often chooses spinal anesthesia. And in order to avoid the impact of drugs on the fetus, before the delivery, anesthesiologist generally don't use sedative or analgesic drugs. Read more about this study

Who is it for?
Ages 23 to 41 years, women only
What is being tested?
Dexmedetomidine
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
40 participants
Where
1 siteChina
Study dates
Jun 2015to Nov 2015
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 23 to 41 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • 40 cases of full-term puerperas with single baby ASA I or II, aged 23 to 41 years old, weighing 61-92 kg, without spinal canal puncture contraindication and scheduled for caesarean section under epidural anesthesia were selected for this study.

Who cannot join

  • women with a history of cardiac, liver, or kidney diseases;
  • women with allergy to amide local anesthetics;
  • women with epilepsy;
  • those taking cardiovascular medications;
  • those with pregnancy-induced hypertension;
  • women with evidence of intrauterine growth restriction or fetal compromise.

Trial locations and contacts

1 site in 1 country.

China1 site
  • The First Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, 210029

Other trials in China

About this study

Official title: Effect and Placental Transfer of Dexmedetomidine During Caesarean Section Under Epidural Anaesthesia

Current cesarean section often chooses spinal anesthesia. And in order to avoid the impact of drugs on the fetus, before the delivery, anesthesiologist generally don't use sedative or analgesic drugs. However, the majority of puerperas would appear nervous, anxiety, fear and other psychological reactions in cesarean section. Although the placental transfer and the foetal metabolism of dexmedetomidine have been reported and the result show no adverse effects on neonates, but the placental transfer of dexmedetomidine in intravertebral anesthesia area was lack of systematical research. This study intends to use of dexmedetomidine in the cesarean section under epidural anesthesia and investigate its effects on the parturients' haemodynamics and the neonates' placental transfer and metabolism.

Read the detailed description

Current cesarean section in domestic and overseas often chooses spinal anesthesia. And in order to avoid the impact of drugs on the fetus, before the delivery, anesthesiologist generally don't use sedative or analgesic drugs. However, the majority of puerperas would appear nervous, anxiety, fear and other psychological reactions in cesarean section, and thus produced a series of stress reactions that not only cause the hemodynamic fluctuating in anesthesia and operation, but also lead to different degrees of personality and behavior changed. It causes serious injury to physical and mental health of patients. Dexmedetomidine is a highly selective α2 receptors agonist (α2-AR) ,it has sedation, analgesia, antisympathetic pharmacological effects and unique "conscious sedation" without respiratory depression. At present, dexmedetomidine has been widely used in patients in clinics and clinical anesthesia, it has been hailed as an"dvocate medicine in modern comfortable anesthesia."Experiments in animals have shown that dexmedetomidine had no adverse effects on pregnant rats. In addition, Dexmedetomidine has successful application in preterm infants, infants and children anesthesia, also has a few for caesarean patients sedation reports. Although the placental transfer and the foetal metabolism of dexmedetomidine have been reported and the result show no adverse effects on neonates, but the placental transfer of dexmedetomidine in intravertebral anesthesia area was lack of systematical research.

The safety of the use of dexmedetomidine on neonatal outcome is a very important issue. Experimental study on acute exposure of rats to dexmedetomidine at the anticipated delivery time recorded absence of any adverse effects on perinatal morphology of pups, their birth weight, crown-rump length, physical growth and postnatal behavioural performances. Others studied the transfer of clonidine and dexmedetomidine across the isolated perfused human placenta. Dexmedetomidine disappeared faster than clonidine from the maternal circulation, while even less dexmedetomidine was transported into the fetal circulation. This was due to its greater placental tissue retention, the basis for which probably is the higher lipophilicity of dexmedetomidine.

Umbilical cord blood gas analysis of umbilical vein and umbilical artery in this study was similar to the results of previous studies . The partial oxygen pressure (PO2) of the arterial blood gas in the umbilical vein was not significantly affected to the oxygen supply of the newborn infants. On the other hand, the umbilical arterial blood gas was the most reliable indicator of the oxygenation index and acid-base status of the fetus. Previous studies have indicated that the relationship between hydrogen ion concentration(PH), base excess(BE) and neonatal asphyxia was relatively large, and it was positively related to growth.

Previous research of in vitro placental perfusion indicated that the transfer rate of dexmedetomidine through the placenta to foetus was 0.77, and the other study indicated that the rate of placental transfer of dexmedetomidine in cesarean section operation under general anesthesia was 0.76. It's indicated that dexmedetomidine can also easily pass through the placental barrier like other anaesthetic drugs. However, the placental transfer rate of dexmedetomidine is much lower than that of clonidine(0.85) and that of remifentanil(0.88), which may be caused by dexmedetomidine being more fat-soluble and easier to be retained in the placenta.

Recently, there is a published interested case report about the successful use of dexmedetomidine 1 µg/kg followed with 1 µg/kg/h for 10 minutes before cesarean delivery to facilitate awake fiberoptic endotracheal intubation patient with spinal muscular atrophy type III with provided adequate sedation, without respiratory compromise. Although pharmacokinetic data cannot be determined, this case confirms existing in vitro data that dexmedetomidine has significant placental transfer. Nevertheless, serious neonatal effects were not detected. Similarly, others used, i.v. dexmedetomidine successfully as an adjunct to opioid-based PCA and general anesthesia for the respective provision of labor analgesia and cesarean delivery anesthesia in a parturient with a tethered spinal cord, with favourable maternal and neonatal outcome.

Project Objectives:

The investigators hypothesize that application of dexmedetomidine in cesarean section under epidural anesthesia was conducive to maintaining the stability of hemodynamics of the patients, reducing patients' anxiety and pain stress during the operations, which also had no adverse effects on newborns.

The aims of the present study are:

Our research efforts will focus on identifying the effects of 0.5 µg/kg/h dexmedetomidine for uncomplicated cesarean delivery on the followings.

Hemodynamic [heart rate, systolic and mean blood pressure] changes. The rate of placental transfer of dexmedetomidine . Apgar score (1 and 5 minute) after delivery. The umbilical cord venous and arterial blood gases analyses. The sedation of Dexmedetomidine. The incidence of the major complications (respiratory, cardiovascular events, nausea, vomiting and other adverse reactions).

Project Design:

Study Design:

The study was approved by the first affiliated hospital ethics committee of Nanjing Medical University, and the puerperas and their families signed informed consent.

Sampling Site:

  1. Patient Selection: patients aged 23-41 years (ASA physical status I-II) scheduled for elective in about 40 women (American Society of Anesthesiologists [ASA] I and II), with uncomplicated, singleton pregnancies, who will receive epidural anesthesia. The investigators will exclude women with a history of cardiac, liver, or kidney diseases; allergy to amide local anesthetics; epilepsy; those taking cardiovascular medications; and those with pregnancy-induced hypertension, evidence of intrauterine growth restriction, or fetal compromise.

II. Anesthesia method

Routine monitoring such as electrocardiogram(ECG), heart rate(HR), saturation of pulse oxygen(SpO2) were monitored after patient arrived at the operation room. Selected the forearm vein to open venous access, infused sodium lactate Ringer's solution before anaesthesia. Then began to epidural anesthesia: The patients were at left side lying position, the L2,3 gap was chosen for puncture. After determined the success of puncture, inserted the epidural catheter into the head side, the length of the epidural space is 4cm. By intraductal injection of 2% lidocaine 3ml, signs of spinal anesthesia were excluded. Additional 0.75% ropivacaine 10 ~ 20ml was injected to control the level of pain disappear on thoracic4(T4) or thoracic6(T6) to satisfy the operation needs. After the level of anesthesia completed, Dex group: dexmedetomidine was continuously infused by 0.5 μg/kg in 10 min, followed with 0.5 μg/kg/hr continuous infusion until the closure of the abdominal. normal saline(NS)group: Pumped in the same volume of normal saline. In the operation, if the blood pressure was lower than 70% before anesthesia given ephedrine 10 ~ 15mg, and 0.5mg atropine was used when the heart rate was lower than 60 beats per minute. All operations were performed by the same group of maieutologists.

III. The Investigators who will be involved with subsequent postoperative patient assessment will be blinded of the patient group.

IV. Observational information

Systolic pressure(SBP) and diastolic blood pressure(DBP), heart rate(HR) were recorded at four time points: before anesthesia(T0), infused 10 min(T1), at the delivery of the baby(T2), at the end of the operation(T3). Ramsay sedation scales were evaluated at three time points: before anesthesia (T0), skin incision (T1) and 10min after delivery (T2). (Ramsay standard for evaluation: 1 point: anxious or restless or both; 2 point: cooperative, orientated and tranquil; 3 point: responding to commands; 4 point: brisk response to stimulus; 5 point: sluggish response to stimulus; 6 point: no response to stimulus. The Apgar scores were evaluated at 1 and 5 minute after the delivery. The urinary volume, the bleeding volume and the infusion volume during the operation were measured. Adverse effects such as nausea and vomiting in 24 hour after the operation were recorded. Postoperative analgesic formula: 12mg butorphanol tartrate, 9mg granisetron hydrochloride, diluted with normal saline to 100ml. Background dose: 2 milliliter per hour, patient controlled analgesia (PCA): 0.5 milliliter, locking time:15 minutes.

  1. Samples Collection and Analysis For blood gas analysis and the plasma dexmedetomidine concentrations:

Maternal venous blood samples (MV), umbilical artery(UA) and umbilical vein(UV) will be collected for blood gas analysis, plasma dexmedetomidine concentrations. concentrations at points: When the baby was born.

  1. Type of samples: centrifuged 3500 revolutions per minute for 5 minutes and separated of plasma to -20℃ frozen preservation.
  2. Laboratory Analysis:

High-performance liquid chromatography-mass spectrometry(HPLC-MS/MS) was then used for measuring the plasma dexmedetomidine concentrations [concentration of umbilical vein(CUV), concentration of umbilical artery(CUA) and concentration of maternal vein(CMV)]..

VI. Statistical Analysis: The statistical analysis was performed with SPSS 22.0. The measurement data are shown as mean ± standard deviation (x±s), the t-test was used for comparison between the groups, and repeated measures analysis of variance was performed for comparison within the group; chi-square test was used for comparison of the count data, and rank-sum test was used for comparison of the level information. p < 0.05 was considered as statistically significant.

VII. Report Writing: 2 months

Being tested
Dexmedetomidine, Placebo
Keywords
Epidural Anaesthesia, Cesarean Section, Dexmedetomidine

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DexmedetomidineDrug

    Also called Dexmedetomidine Hydrochloride Injection

    The dexmedetomidine groups (n = 20 ) will receive i.v. infusion of 0.5 μg/kg of solution containing 5 µg/mL of dexmedetomidine, at 10 min after the level of anesthesia completed. Followed with 0.1ml/kg/hr continuous infusion until the closure of the abdominal.The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.

  • PlaceboDrug

    The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.

Study groups in NCT02715154
Study groupRoleWhat they receive
Dexmedetomidine 0.5 µg/kg/hActive comparatorSolution containing 5 µg/mL of dexmedetomidine was continuously infused by 0.5 μg/kg in 10 min, followed with 0.1 ml/kg/hr continuous infusion until the closure of the abdominal.
Receives: Drug: Dexmedetomidine
PlaceboPlacebo comparatorThe placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal.
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Systolic blood pressure of Dexmedetomidine in Epidural Anaesthesia

    identifying the effects of 0.5 µg/kg/h dexmedetomidine for systolic blood pressure changes.

    Measured: before anesthesia, infused 10 min, at the delivery of the baby, at the end of the operation

  2. Diastolic blood pressure of Dexmedetomidine in Epidural Anaesthesia

    identifying the effects of 0.5 µg/kg/h dexmedetomidine for diastolic blood pressure changes.

    Measured: before anesthesia, infused 10 min, at the delivery of the baby, at the end of the operation

  3. Saturation of pulse oxygen of Dexmedetomidine in Epidural Anaesthesia

    identifying the effects of 0.5 µg/kg/h dexmedetomidine for saturation of pulse oxygen changes.

    Measured: before anesthesia, infused 10 min, at the delivery of the baby, at the end of the operation

  4. Heart rate of Dexmedetomidine in Epidural Anaesthesia

    identifying the effects of 0.5 µg/kg/h dexmedetomidine for heart rate changes.

    Measured: before anesthesia, infused 10 min, at the delivery of the baby, at the end of the operation

Secondary outcomes (6)
  1. Apgar score related to treatment

    Apgar score:The Apgar scores were evaluated at 1 and 5 minute after the delivery.

    Measured: 1 and 5 minute after delivery

  2. Blood gas analysis

    The difference of blood gas analysis from MV, UA , UV.

    Measured: at the delivery of the baby

  3. adverse events

    Major complications (respiratory, cardiovascular events, nausea, vomiting and other adverse reactions)

    Measured: intraoperative and in 48 hours after surgery

  4. plasma concentrations of dexmedetomidine

    identifying the effects of 0.5 µg/kg/h dexmedetomidine for the plasma dexmedetomidine concentrations (CUV, CUA and CMV).

    Measured: at the delivery of the baby

  5. sedation of Dexmedetomidine in Epidural

    identifying the effects of 0.5 µg/kg/h dexmedetomidine for Ramsay sedation scales.(Ramsay standard for evaluation: 1 point: anxious or restless or both; 2 point: cooperative, orientated and tranquil; 3 point: responding to commands; 4 point: brisk response to stimulus; 5 point: sluggish response to stimulus; 6 point: no response to stimulus.)

    Measured: before anesthesia, skin incision and 10min after delivery

  6. Placental Transfer of Dexmedetomidine in Epidural

    identifying the effects of 0.5 µg/kg/h dexmedetomidine for the rate of placental transfer of dexmedetomidine(CUV/CMV).

    Methods:

    When the baby was born, we double clamped the umbilical cord,and extracted 3ml blood from the maternal vein(MV) on the no venous route hand, umbilical artery(UA) and umbilical vein(UV) from the isolated placenta. The blood blood from Dex group were injected heparin sodium anticoagulant tube, centrifuged 3500 revolutions per minute for 5 minutes and separated of plasma to -20℃ frozen preservation. High-performance liquid chromatography-mass spectrometry(HPLC-MS/MS) was then used for measuring the plasma dexmedetomidine concentrations (CUV, CUA and CMV). The rate of placental transfer of dexmedetomidine is CUV/CMV.

    Measured: at the delivery of the baby

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Mar 2016 (estimated)
  2. Study startJun 2015
  3. Primary completionNov 2015
  4. Study completionNov 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02715154
Sponsor's protocol ID
JSPH-A-1
Status last verified
Mar 2017
First submitted
2 Mar 2016
Last updated
28 Mar 2017
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Dexmedetomidine in people with Cesarean Section, Affecting Fetus or Newborn, run by The First Affiliated Hospital with Nanjing Medical University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Systolic blood pressure of Dexmedetomidine in Epidural Anaesthesia (time frame: before anesthesia, infused 10 min, at the delivery of the baby, at the end of the operation). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Mar 2017.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in